Dr. Haitao Xu 徐海涛
Chief Physician, Associate Professor
Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgery-based comprehensive treatment for digestive tract tumors, including those of the liver, gallbladder, spleen, pancreas, and gastrointestinal tract.
Dr. Xu graduated from Harbin Medical University in 1999 with a master’s degree and earned a doctorate in oncology in 2005. Currently a Chief Physician and Associate Professor in the Hepatobiliary and Pancreatic Surgery Department at Harbin Medical University Cancer Hospital, Dr. Xu has extensive clinical experience in hepatobiliary, colorectal, gastrointestinal, and breast surgery.
Professional roles
- Council Member, Heilongjiang Anti-Cancer Association
- Vice Chair, Neuroendocrine Tumor Professional Committee, Heilongjiang Anti-Cancer Association
- Editorial Board Member, Liver Cancer (Electronic Magazine)
Name order: in Chinese the family name comes first (Xu Haitao). Papers usually list the name as Haitao Xu or Xu H.
Selected publications
12 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2025 (senior author): Prealbumin predicts metachronous liver metastasis in colorectal cancer. PubMed 41291567
- Cell Biol Toxicol, 2025 (first author): CUL1-neddylation contributes to K29-linked ubiquitination on p27 for autophagic degradation in sorafenib-resistant liver cancer. PubMed 40111576
- Transl Oncol, 2023 (first author): Long noncoding RNA DLEU1 promotes proliferation and glycolysis of gastric cancer cells via APOC1 upregulation by recruiting SMYD2 to induce trimethylation of H3K4 modification. PubMed 37478669
- PLoS One, 2014 (first author): MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PubMed 25531114
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion